Custom Search Insider Trading Activity Insider Trading Activity
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Custom Search Insider Trading Activity
Updated Dec 9, 2019
Ticker
|
Company Name
|
Qty.
|
Price
|
Size ($)
|
Filing Date
|
Type
|
Δ Own
|
Own
|
Insider Names
|
Title
|
Trade Dates
|
Is Scheduled
| |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 5
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Jan 3 - Jan 4
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 25.67K |
—
|
—
| +44.22% | 83.72K | +1 |
Jan 25
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 7
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Feb 18
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 9
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 25.67K |
—
|
—
| +28.24% | 116.57K | +1 |
Jan 25
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 60K |
—
|
—
| +82.00% | 133.17K | +1 |
Dec 6
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 10
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 25K |
—
|
—
| +51.90% | 73.17K | +1 |
Nov 18
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Nov 18
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 2K |
$2.14 | $4,272.42 | +4.33% | 48.17K | +1 |
Jun 9
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 6
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Dec 21
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 |
Jun 14
| ||||||
Cyclacel Pharmaceuticals, Inc.
| 48.17K |
—
|
—
|
∞
| 46.17K | +1 |
Mar 27
| ||||||
Cyclacel Pharmaceuticals, Inc.
|
0
|
—
|
—
|
—
|
0
| +1 | |||||||
It looks like there's no data for these filter options. Maybe you'll be interested in these options instead. |